Featured Research

from universities, journals, and other organizations

First Derivation Of Human Embryonic Stem Cells Reported In Science

Date:
November 9, 1998
Source:
Geron Corporation
Summary:
Human embryonic stem cells (hES cells) -- unique cells capable of forming all the different cell types and tissues in the body -- have been successfully derived and maintained in culture for the first time by scientists at the University of Wisconsin-Madison, according to an article to be published in the November 6 issue of the journal Science. The research was led by James A. Thomson, VMD, Ph.D., Developmental Biologist at UW-Madison, and was supported by and is licensed to Geron Corporation (NASDAQ:GERN).

Geron Holds Worldwide License to a Breakthrough Discovery with Promise for Treating Degenerative Diseases

MENLO PARK, CA -- November 5, 1998 -- Human embryonic stem cells (hES cells) -- unique cells capable of forming all the different cell types and tissues in the body -- have been successfully derived and maintained in culture for the first time by scientists at the University of Wisconsin-Madison, according to an article to be published in the November 6 issue of the journal Science. The research was led by James A. Thomson, VMD, Ph.D., Developmental Biologist at UW-Madison, and was supported by and is licensed to Geron Corporation (NASDAQ:GERN).

"These cells are different from all other human stem cells isolated to date," said Dr. Thomson. "As the source of all cell types, they hold great promise for use in transplantation medicine, drug discovery and development, and the study of human developmental biology."

The Embryonic Stem Cell

Embryonic stem cells are derived from the inner cell mass of the blastocyst formed during early embryogenesis. Distinguished from all other stem cells, they are pluripotent, able to develop into virtually any and all cells and tissues in the body; and, consistent with their expression of telomerase, self-renewing, a potentially limitless source of cells.

"Geron is focused on developing products to treat age-related degenerative diseases. The availability of hES cells opens extraordinary opportunities for tissue transplantation, and for developing cell and gene therapy products with breakthrough medical potential," said Thomas Okarma, Ph.D., M.D., Geron's vice president of research and development. "Further, Gerons proprietary telomerase technology for prolonging the replicative lifespan of cells derived from hES cells positions the company to potentially supply the preferred cells for transplantation medicine."

Broad Potential for Medicine, Science and Drug Discovery

Human embryonic stem cells hold enormous promise for transplantation medicine because they can potentially produce unlimited quantities of any cell or tissue in the body. In addition, they may be genetically altered to improve therapeutic value, for instance, to prevent immune system rejection by transplant recipients. Examples of cells that Geron may develop for transplantation therapies include heart muscle cells for use in repairing the tissue damage inflicted by heart attacks, blood forming cells for use in bone marrow transplantation procedures for cancer patients, and nerve cells for use in treating patients with Parkinsons disease, stroke or Alzheimers disease.

Human embryonic stem cells also represent a new technology for pharmaceutical research and development. Geron plans to generate a variety of different cell types for use in drug screening and toxicology testing. In addition, hES cells can potentially be engineered to create in vivo models of human disease for drug development as a superior alternative to current mouse models. For example, brain neurons derived from hES cells might be engineered to develop the characteristics of Alzheimers disease and used to discover effective drug treatments.

Human embryonic stem cells should also further our understanding of embryonic development with potential applications toward the treatment of infertility and premature pregnancy loss, and the diagnosis and prevention of birth defects.

Finally, hES cells open the door to a new field of research -- the genomics of human developmental biology. Until now, early genetic events in human embryology have been largely inaccessible to direct observation. Research with hES cells may lead to the discovery of novel genes that fundamentally control tissue differentiation. These gene products could result in the development of therapeutic drugs and proteins with potential applications in wound healing, stroke, heart attack and spinal cord injury.

Collaborations with ES Cell Leaders

To accomplish its hES cell program objectives, Geron has established collaborations with renowned researchers in the field. The company funds research by and holds worldwide licensing agreements with John D. Gearhart, M.D., Ph.D., professor of gynecology and obstetrics at Johns Hopkins University School of Medicine, and Roger A. Pedersen, Ph.D., professor at the University of California, San Francisco.

Next steps in Geron's hES cell program include the development and optimization of enabling technologies. These include techniques for the production and scale up of hES cells; the identification of cell differentiation factors; techniques for genetically engineering hES cells, and the development of models to test proposed transplant products.

"As we pursue these next steps, Geron recognizes that research in this field should be conducted according to appropriate guidelines," said Ronald W. Eastman, Gerons president and CEO. "This discovery holds great promise for the treatment of a variety of human diseases and conditions. In concert with our Ethics Advisory Board and the Institutional Review Boards of our collaborators, Geron is committed to realizing the vast potential of this technology in a responsible manner."

Geron Corporation is a biopharmaceutical company focusing on discovering and developing therapeutic and diagnostic products based upon the company's understanding of human embryonic stem cells, and of telomeres and telomerase in cells -- fundamental biological platforms underlying cancer and other age-related degenerative diseases.

The company desires to take advantage of the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Specifically, the company wishes to alert readers that the matters discussed in this press release constitute forward-looking statements that are subject to certain risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect the company's results are included in the company's quarterly report on Form 10-Q for the quarter ended June 30, 1998.


Story Source:

The above story is based on materials provided by Geron Corporation. Note: Materials may be edited for content and length.


Cite This Page:

Geron Corporation. "First Derivation Of Human Embryonic Stem Cells Reported In Science." ScienceDaily. ScienceDaily, 9 November 1998. <www.sciencedaily.com/releases/1998/11/981109085805.htm>.
Geron Corporation. (1998, November 9). First Derivation Of Human Embryonic Stem Cells Reported In Science. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/1998/11/981109085805.htm
Geron Corporation. "First Derivation Of Human Embryonic Stem Cells Reported In Science." ScienceDaily. www.sciencedaily.com/releases/1998/11/981109085805.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) — You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) — The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) — Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) — New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins